Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines
- 1 January 2005
- journal article
- review article
- Published by Wiley in Journal of Medical Virology
- Vol. 78 (2), 169-177
- https://doi.org/10.1002/jmv.20524
Abstract
Hepatitis B vaccines are highly effective and safe and have been incorporated into national immunization programs in over 150 countries. The major humoral immune response is to the common a determinant of the surface antigen protein of the virus. Approximately 5–10% of healthy immunocompetent subjects do not mount an antibody response (anti‐HBs). Non‐response is associated with different HLA‐DR alleles and impaired Th cell response, among other factors such as route of injection, age, gender, body mass, and other factors. Important hepatitis B surface antigen variants have also been identified, which may have a potential impact on immunization and routine screening of blood, blood products and tissues, and organs for transplantation. Strategies for hepatitis B immunization are reviewed. Over 1,000 million doses of hepatitis B vaccine have been used with an outstanding record of safety. There is no evidence of an association between hepatitis B vaccines and the sudden infant death syndrome, chronic fatigue syndrome, and multiple sclerosis (MS). Several studies are in progress on treatment of chronic hepatitis B infection by immunization with multiple antigenic components, combination of vaccine with antiviral drugs and cytokines, T cell vaccines, DNA vaccines alone or with DNA encoded immunomodulatory cytokines, and direct genetic manipulation of antigen presenting cells. J. Med. Virol. 78:169–177, 2006.Keywords
This publication has 28 references indexed in Scilit:
- Most humoral non-responders to hepatitis B vaccines develop HBV-specific cellular immune responsesVaccine, 2004
- Therapeutic Vaccines for Chronic InfectionsScience, 2004
- DNA‐based immunotherapy: potential for treatment of chronic viral hepatitis?Reviews in Medical Virology, 2002
- Vaccinations and the Risk of Relapse in Multiple SclerosisNew England Journal of Medicine, 2001
- Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in taiwanHepatology, 1999
- A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virusHepatology, 1999
- Molecular epidemiology of hepatitis B virus vaccine variants in SingaporeVaccine, 1995
- Site of injection for vaccination.BMJ, 1992
- Vaccine-induced escape mutant of hepatitis B virusThe Lancet, 1990
- Genetic Prediction of Nonresponse to Hepatitis B VaccineNew England Journal of Medicine, 1989